Navigation Links
Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
Date:1/7/2009

SEATTLE, Jan. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that they received $7.5 million pursuant to the joint venture transaction with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) in the United States. In December, the Company received the initial $7.5 million payment in connection with the closing of such transaction. The Company may earn up to an additional $15 million in product sales milestone payments upon achievement of certain revenue targets.

Zevalin, a radioimmunotherapeutic, was exclusively marketed by CTI in the United States since December, 2007 and is now marketed jointly by CTI and Spectrum through RIT Oncology, LLC ("RIT") for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients who have rituximab-refractory follicular NHL. CTI holds a sale option exercisable from January 15, 2009 through July 15, 2009 in its sole discretion to sell its 50% membership interest in RIT to Spectrum for $18 million. The FDA has accepted for filing and review, and has granted priority review status for a supplemental Biologics License Application (sBLA) for use of Zevalin as consolidation therapy in patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy and expects a decision regarding the sBLA in early April, 2009.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a sur
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... ... Sufferers , ... March 30, 2010 -- Those with aching backs might want to look at their home ... color schemes and price range, but many don,t take time to consider products that can ...
... ... ... Tahitian Noni International (TNI) announced that their 2011 International Leadership Conference would ... of the most luxurious cruise ships in the world. The announcement was received with such ...
... ... improved longevity , ... YORK (PRWEB) March 30, 2010 -- CogniFit™, Inc., a leading maker of Brain Fitness ... longevity, author and speaker, is now an official spokesperson for CogniFit. Berg, who is ...
... ... For New Web Hosting Sign-ups , ... Vancouver, Canada (PRWEB) March 30, 2010 -- Canadian Web Hosting ( ... announced an increase of benefits for their popular affiliate program. The immediate increase from ...
... Boston University School of Medicine found that women with serum ... risk of developing gout than men. This study, the ... gout risk in women, also evaluated purported risk factors for ... and diuretic use to be among leading contributors for women. ...
... What makes some viral infections fatal and others much ... that a part of the variability can be attributed ... Professor Michael Katze, presenting at the Society for General ... modelling could be a powerful tool to allow treatments ...
Cached Medicine News:Health News:Proper Home Dcor May Assist in Alleviating Back Pain 2Health News:Proper Home Dcor May Assist in Alleviating Back Pain 3Health News:Caribbean Cruise Announced by Tahitian Noni International for 2011 2Health News:CogniFit and Longevity Expert Cooperate to Raise Awareness for the Benefits of Brain Fitness 2Health News:CogniFit and Longevity Expert Cooperate to Raise Awareness for the Benefits of Brain Fitness 3Health News:Canadian Web Hosting Increases Affiliate Incentive 2Health News:Obesity, hypertension, alcohol and diuretic use -- gout risk factors for women 2Health News:Personalizing medicine to prevent pandemics 2
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... Soft, foam-lined FoamWrap ThumWrap Splints offer support ... Ideal to relieve mild pain or strain ... activities. Choose either the rigid or the ... amount of support. Washable and breathable, the ...
... lightweight orthosis is designed to comfortably restrict ... holding the hand in a neutral position. ... grade thermoplastic whose unique characteristics offer durable ... provides rigid cast-like immobilization of the wrist, ...
... is a custom wrist orthotic designed to limit the ... patient's maximum range-of-motion. , ,Indications: , Wrist ... fibrocartilage complex , Coles fracture - distal ... Partial tendon rupture , ORIF - Open ...
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
Medicine Products: